SecondWave Systems Secures $7 Million to Revolutionize Anti-Inflammatory Treatments Using Ultrasound Technology

SecondWave Systems, a forward-thinking medical device company, has successfully secured $7 million in Series A funding to advance its pioneering ultrasound-based therapy for inflammatory disorders. This funding round was led by Treo Ventures, alongside major strategic partners in healthcare, and supported by Scientific Health Development, as well as the University of Minnesota's Discovery Capital and SSBCI funds.

The funds raised will facilitate the next clinical study for SecondWave Systems' innovative technology, following the promising results from their initial human study, which indicated a notable decrease in rheumatoid arthritis disease activity. This success serves as a critical stepping stone as the company strives to enhance the quality of life for millions suffering from chronic inflammatory conditions.

The new investment comes after initial funding from U.S. government entities, including DARPA and ARPA-H, which played instrumental roles in the research and development of the SecondWave MINI™, a groundbreaking noninvasive and wearable therapeutic ultrasound device aimed at addressing inflammatory disorders.

Anuj Bhardwaj, CEO of SecondWave Systems, expressed enthusiasm about this new phase of development, stating, "We are excited to enter this next stage of growth with a strong coalition of new investor partners. Our mission at SecondWave is clear: to improve the lives of patients dealing with chronic inflammatory diseases."

Mudit K. Jain, General Partner at Treo Ventures, noted the potential impact of SecondWave’s novel therapy, saying, "We’re thrilled to partner with SecondWave's adept team to further this innovative therapy, enhancing patients' lives while simultaneously aiming to reduce healthcare costs."

Dr. Paul Peter Tak, an influential figure in biotech and a member of the SecondWave advisory board, highlighted the promise of this noninvasive approach. Known for his contributions to bioelectronic medicine in treating autoimmune diseases, he commented that the use of ultrasound therapy specifically for immune-mediated inflammatory conditions could see widespread adoption due to its innovative nature.

SecondWave Systems is on a path to revolutionize the treatment landscape for inflammatory diseases with its unique, first-of-its-kind ultrasound stimulation platform. The SecondWave MINI device utilizes proprietary low-intensity focused ultrasound technology to stimulate the spleen, with aspirations to manage both acute and chronic inflammatory disorders efficiently. Ongoing clinical studies are focusing on various inflammatory conditions, including rheumatoid arthritis, showing the potential breadth of application for this technology.

This upcoming clinical study represents not just an evolution in treatment but a lifeline to patients seeking non-invasive solutions for their chronic conditions. The commitment from SecondWave to innovate within the healthcare space is poised to significantly alter the treatment options available, making it a company to watch in the coming years.

For further details, you can visit SecondWave Systems’ official website.